Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) had its price objective boosted by research analysts at Citigroup from $16.00 to $17.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s price target points to a potential upside of 118.37% from the stock’s current price.
Other research analysts have also recently issued research reports about the stock. HC Wainwright upped their price target on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Leerink Partners initiated coverage on shares of Oric Pharmaceuticals in a research note on Monday, October 5th. They issued an “outperform” rating and a $26.00 price objective for the company. Stifel Nicolaus raised their price target on Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, October 26th. Wedbush decreased their price objective on shares of Oric Pharmaceuticals from $17.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 27th. Finally, JPMorgan Chase & Co. boosted their target price on Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Fourteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $21.33.
Check Out Our Latest Research Report on ORIC
Oric Pharmaceuticals Stock Performance
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last issued its earnings results on Monday, November 16th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.05). Equities research analysts forecast that Oric Pharmaceuticals will post -1.53 earnings per share for the current fiscal year.
Insider Buying and Selling at Oric Pharmaceuticals
In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 77,000 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total value of $1,054,130.00. Following the completion of the sale, the chief financial officer owned 69,828 shares in the company, valued at approximately $955,945.32. This represents a 52.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 105,000 shares of company stock worth $1,432,952. 5.70% of the stock is owned by insiders.
Institutional Trading of Oric Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Oric Pharmaceuticals during the 2nd quarter worth $73,904,000. Siren L.L.C. increased its holdings in shares of Oric Pharmaceuticals by 197.6% during the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock valued at $37,987,000 after acquiring an additional 1,990,617 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Oric Pharmaceuticals by 19.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock worth $18,637,000 after buying an additional 244,060 shares during the period. Algert Global LLC lifted its position in Oric Pharmaceuticals by 791.3% during the 2nd quarter. Algert Global LLC now owns 1,215,293 shares of the company’s stock worth $13,162,000 after acquiring an additional 1,078,943 shares during the period. Finally, Braidwell LP lifted its holdings in shares of Oric Pharmaceuticals by 7.7% during the second quarter. Braidwell LP now owns 1,214,540 shares of the company’s stock worth $13,153,000 after purchasing an additional 86,500 shares during the period. 95.05% of the stock is currently owned by institutional investors.
About Oric Pharmaceuticals
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
See Also
- Five stocks we like better than Oric Pharmaceuticals
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
